SCTX — Scribe Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $330.17m
- $445.31m
- $51.17m
Annual cashflow statement for Scribe Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -47.8 | -21.8 |
| Depreciation | ||
| Non-Cash Items | 4.88 | 9.91 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | -5.22 | -36.4 |
| Change in Accounts Receivable | ||
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Other Liabilities | ||
| Cash from Operating Activities | -45.2 | -45.2 |
| Capital Expenditures | -1.35 | -1.27 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | 14.4 | 46.5 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | 13 | 45.3 |
| Financing Cash Flow Items | -0.69 | 0 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Cash from Financing Activities | -0.222 | 0.142 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | -32.4 | 0.194 |